Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes.
The co-existence of mutations in the BRCA1 and BRCA2 genes is unusual, and to date almost all cases reported have had at least one of the Ashkenazi founder mutations. We report on a family in whom individuals are double heterozygotes for a mutation in BRCA1 and a novel splice site mutation in BRCA2. The phenotypes are discordant, where one sister has had multiple cancers in the BRCA spectrum, while the other is unaffected at 65 years of age. The utility of testing is discussed, and the completion of diagnostic testing despite the finding of a potentially causal mutation is validated.
Smith
Margaret
M
Melbourne Health, Parkville, VIC, Australia.
Fawcett
Susan
S
Sigalas
Emanouil
E
Bell
Richard
R
Devery
Sophie
S
Andrieska
Nikolina
N
Winship
Ingrid
I
D000328:Adult; D000368:Aged; D019313:BRCA1 Protein / Q000235:genetics; D024682:BRCA2 Protein / Q000235:genetics; D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics*; D005260:Female; D018703:Founder Effect; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D005838:Genotype; D006579:Heterozygote; D006801:Humans; D007585:Jews / Q000235:genetics*; D008875:Middle Aged; D009154:Mutation; D010375:Pedigree; D010641:Phenotype; D016133:Polymerase Chain Reaction; D011159:Population Surveillance; D018570:Risk Assessment; D012307:Risk Factors
D019313:BRCA1 Protein; D024682:BRCA2 Protein